JP2013533745A - ノロウイルスに由来する免疫原性組成物および方法 - Google Patents

ノロウイルスに由来する免疫原性組成物および方法 Download PDF

Info

Publication number
JP2013533745A
JP2013533745A JP2013518791A JP2013518791A JP2013533745A JP 2013533745 A JP2013533745 A JP 2013533745A JP 2013518791 A JP2013518791 A JP 2013518791A JP 2013518791 A JP2013518791 A JP 2013518791A JP 2013533745 A JP2013533745 A JP 2013533745A
Authority
JP
Japan
Prior art keywords
norovirus
strain
chimeric
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533745A5 (enExample
Inventor
イーサン セッテンバー，
アンジェリカ メディナ−セルビー，
ドリス コイト，
フィリップ ドルミッツァー，
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013533745A publication Critical patent/JP2013533745A/ja
Publication of JP2013533745A5 publication Critical patent/JP2013533745A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013518791A 2010-07-06 2011-07-05 ノロウイルスに由来する免疫原性組成物および方法 Pending JP2013533745A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36158110P 2010-07-06 2010-07-06
US61/361,581 2010-07-06
PCT/US2011/042979 WO2012006293A1 (en) 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016000962A Division JP6351641B2 (ja) 2010-07-06 2016-01-06 ノロウイルスに由来する免疫原性組成物および方法

Publications (2)

Publication Number Publication Date
JP2013533745A true JP2013533745A (ja) 2013-08-29
JP2013533745A5 JP2013533745A5 (enExample) 2014-08-14

Family

ID=44628871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013518791A Pending JP2013533745A (ja) 2010-07-06 2011-07-05 ノロウイルスに由来する免疫原性組成物および方法
JP2016000962A Active JP6351641B2 (ja) 2010-07-06 2016-01-06 ノロウイルスに由来する免疫原性組成物および方法
JP2018030649A Withdrawn JP2018086020A (ja) 2010-07-06 2018-02-23 ノロウイルスに由来する免疫原性組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016000962A Active JP6351641B2 (ja) 2010-07-06 2016-01-06 ノロウイルスに由来する免疫原性組成物および方法
JP2018030649A Withdrawn JP2018086020A (ja) 2010-07-06 2018-02-23 ノロウイルスに由来する免疫原性組成物および方法

Country Status (8)

Country Link
US (3) US20130171185A1 (enExample)
EP (2) EP3153578A1 (enExample)
JP (3) JP2013533745A (enExample)
CN (1) CN103154242B (enExample)
AU (1) AU2011276328C1 (enExample)
CA (1) CA2804501C (enExample)
MX (1) MX2013000163A (enExample)
WO (1) WO2012006293A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019149996A (ja) * 2018-03-06 2019-09-12 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
JP2020515531A (ja) * 2017-03-28 2020-05-28 チルドレンズ ホスピタル メディカル センター ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
JP2021524273A (ja) * 2018-07-13 2021-09-13 メディカゴ インコーポレイテッド 改変ノロウイルスｖｐ１タンパク質および改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
US12539327B2 (en) 2023-10-19 2026-02-03 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
CA2804492A1 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
JP2013537518A (ja) 2010-07-06 2013-10-03 ノバルティス アーゲー ＲＮＡ送達に有利なｐＫａ値を有する脂質を含むリポソーム
FI4066857T3 (fi) 2010-08-31 2023-03-20 Glaxosmithkline Biologicals Sa Pegyloituja liposomeja immunogeeniä koodaavan rna:n kuljettamiseksi
RU2597974C2 (ru) 2010-10-11 2016-09-20 Новартис Аг Платформы доставки антигенов
WO2013006838A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
AU2014204826A1 (en) * 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
US9975923B2 (en) * 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
EP2970395A4 (en) * 2013-03-15 2017-03-29 The University of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US20160038586A1 (en) * 2014-08-07 2016-02-11 Medigen Biotechnology Corp. Virus-like Particle Vaccines
EP3307239B1 (en) * 2015-06-12 2020-09-16 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
CN107034198B (zh) 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
WO2017160124A2 (ko) * 2016-03-18 2017-09-21 연세대학교 산학협력단 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
KR101914779B1 (ko) 2016-03-18 2018-11-02 (주)인테라 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
WO2017214557A1 (en) 2016-06-10 2017-12-14 Counsyl, Inc. Nucleic acid sequencing adapters and uses thereof
CA3037366A1 (en) 2016-09-29 2018-04-05 Myriad Women's Health, Inc. Noninvasive prenatal screening using dynamic iterative depth optimization
US10968447B2 (en) 2017-01-31 2021-04-06 Myriad Women's Health, Inc. Methods and compositions for enrichment of target polynucleotides
WO2018144217A1 (en) 2017-01-31 2018-08-09 Counsyl, Inc. Methods and compositions for enrichment of target polynucleotides
WO2018170603A1 (en) 2017-03-23 2018-09-27 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins
US11232850B2 (en) 2017-03-24 2022-01-25 Myriad Genetics, Inc. Copy number variant caller
EP3717648A4 (en) 2017-11-30 2021-12-01 Medicago Inc. MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS WITH MODIFIED NOROVIRUS VP1 PROTEINS
WO2020182860A1 (en) * 2019-03-12 2020-09-17 Icon Genetics Gmbh Norovirus-like particles with improved stability
BR112022013537A2 (pt) * 2020-01-08 2022-11-22 Bharat Biotech Int Ltd Composições de vacina viral e métodos de preparações das mesmas
CN114316033A (zh) * 2020-09-29 2022-04-12 香港理工大学深圳研究院 一种特异性识别诺如病毒的单克隆抗体及制备方法与应用
CN115161343B (zh) * 2021-04-01 2024-06-04 苏州相奕生物技术有限公司 一种重组腺病毒表达载体及以其制备的多价诺如病毒疫苗
EP4422681A4 (en) * 2021-10-27 2025-11-19 Univ Pennsylvania VACCINE AGAINST A NOROVIRUS AND METHODS OF USE
WO2024144272A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 노로바이러스 gii mrna를 포함하는 백신 조성물
WO2024144262A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 노로바이러스 gi mrna를 포함하는 백신 조성물
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039229A2 (en) * 2007-09-18 2009-03-26 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2009516529A (ja) * 2005-11-22 2009-04-23 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
WO2010017542A1 (en) * 2008-08-08 2010-02-11 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
AU4851493A (en) 1992-09-07 1994-03-29 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AU756828B2 (en) 1997-12-02 2003-01-23 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
FR2771751B1 (fr) 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris Erythrovirus et ses applications
EP1053015A2 (en) 1998-02-12 2000-11-22 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
IL142395A0 (en) 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
ES2398413T3 (es) 1999-06-22 2013-03-19 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Kit de detección de SRSV
MXPA02003067A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Uso de combinacion de ester sorbitano de polioxietileno y octoxinol como adjuvante y su uso en vacunas.
MXPA02003068A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Adyuvante que comprende un eter o ester alquilo de polioxietileno y al menos un tensioactivo no ionico..
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
ES2505700T3 (es) 2000-06-01 2014-10-10 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados
CN1256591C (zh) 2000-06-15 2006-05-17 希龙公司 Hcv抗原/抗体组合试验
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
US7527802B2 (en) 2001-02-13 2009-05-05 The United States Of America As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
EP1377299A4 (en) 2001-03-19 2009-11-11 Intercell Usa Inc TRANSCUTANE IMMUNOSTIMULATION
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
GB0123756D0 (en) 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
WO2003068925A2 (en) 2002-02-11 2003-08-21 Mosca Joseph D Production of a protein delivery system for in vivo therapeutic treatment
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
EP1500699A1 (en) 2003-07-22 2005-01-26 Vivalis Production of vaccinia virus with adherent or non adherent avian cell lines
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1670824A2 (en) 2003-09-24 2006-06-21 Montana State University Norovirus monoclonal antibodies and peptides
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
CA2567254C (en) 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
AU2006309286A1 (en) 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
US9150882B2 (en) 2006-01-31 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
CN101153341B (zh) * 2007-09-21 2010-12-15 珠海市疾病预防控制中心 诺如病毒gⅱ型检测用引物、检测方法、检测试剂盒
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
WO2010006238A2 (en) 2008-07-11 2010-01-14 The Administrators Of The Tulane Educational Fund Stimulus-responsive apta-chelamers
DK2853545T3 (en) 2008-09-17 2016-08-29 Xencor Inc Antibody specific for IgE
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
UA107921C2 (en) 2008-11-26 2015-03-10 Amgen Inc Variants of polypeptide of receptor ivr activin and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009516529A (ja) * 2005-11-22 2009-04-23 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
WO2009039229A2 (en) * 2007-09-18 2009-03-26 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
WO2010017542A1 (en) * 2008-08-08 2010-02-11 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015027395; ＴＡＮ，　Ｍｉｎｇ　ｅｔ　ａｌ．: '"Ｔｈｅ　Ｐ　ｄｏｍａｉｎ　ｏｆ　ｎｏｒｏｖｉｒｕｓ　ｃａｐｓｉｄ　ｐｒｏｔｅｉｎ　ｆｏｒｍｓ　ｄｉｍｅｒ　ａｎｄ　ｂｉｎｄｓ　ｔｏ　ｈｉｓｔｏ-ｂｌｏｏｄ　ｇｒｏｕｐ　ａｎｔｉｇｅｎ　ｒｅｃｅｐｔｏ' Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．　７８, 2004, ｐ．　６２３３-６２４２ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515531A (ja) * 2017-03-28 2020-05-28 チルドレンズ ホスピタル メディカル センター ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
JP7641695B2 (ja) 2017-03-28 2025-03-07 チルドレンズ ホスピタル メディカル センター ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
JP2019149996A (ja) * 2018-03-06 2019-09-12 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
JP2021524273A (ja) * 2018-07-13 2021-09-13 メディカゴ インコーポレイテッド 改変ノロウイルスｖｐ１タンパク質および改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ
JP7429684B2 (ja) 2018-07-13 2024-02-08 メディカゴ インコーポレイテッド 改変ノロウイルスｖｐ１タンパク質および改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ
JP7429684B6 (ja) 2018-07-13 2024-03-15 メディカゴ インコーポレイテッド 改変ノロウイルスｖｐ１タンパク質および改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
KR20240145520A (ko) 2022-03-18 2024-10-07 덴카 주식회사 링커에 의해 연결된 캡시드 단백질을 포함하는 바이러스 유사입자
US12539327B2 (en) 2023-10-19 2026-02-03 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same

Also Published As

Publication number Publication date
AU2011276328B2 (en) 2015-07-09
MX2013000163A (es) 2013-03-05
CN103154242B (zh) 2015-09-30
CA2804501C (en) 2021-01-26
US10065994B2 (en) 2018-09-04
AU2011276328C1 (en) 2016-01-21
AU2011276328A1 (en) 2013-02-28
EP2591097A1 (en) 2013-05-15
WO2012006293A1 (en) 2012-01-12
US10287324B2 (en) 2019-05-14
EP3153578A1 (en) 2017-04-12
US20160222066A1 (en) 2016-08-04
US20190023746A1 (en) 2019-01-24
JP2018086020A (ja) 2018-06-07
CN103154242A (zh) 2013-06-12
CA2804501A1 (en) 2012-01-12
US20130171185A1 (en) 2013-07-04
JP2016053087A (ja) 2016-04-14
JP6351641B2 (ja) 2018-07-04

Similar Documents

Publication Publication Date Title
JP6351641B2 (ja) ノロウイルスに由来する免疫原性組成物および方法
US9744228B2 (en) Method for generating a parvovirus B19 virus-like particle
JP5215865B2 (ja) ノロウイルス抗原およびサポウイルス抗原
CN116438195A (zh) 用于针对轮状病毒疫苗接种的融合蛋白质
Crisci et al. Chimeric calicivirus-like particles elicit protective anti-viral cytotoxic responses without adjuvant
US20230321219A1 (en) SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS [SARS-CoV-2]-VIRUS-LIKE PARTICLE [VLP] VACCINE: COMPOSITIONS, DELIVERY STRATEGIES, METHODS AND USES
US20250339512A1 (en) Self-cleaving polyproteins and uses thereof
CN116438202A (zh) 包含圆环病毒科衣壳蛋白的融合蛋白及其构成的嵌合病毒样颗粒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160203